Nanjing Delova Biotech Co., Ltd. ("Delova") today announced positive results from two pivotal Phase 3 clinical trials ...
Obexelimab is a monoclonal antibody designed to bind both CD19 and FcγRIIb receptors and inhibit the activity of B-cells linked to autoimmune diseases.
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive statistically significant results from the 8-week ...
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (ROIV) today announced positive results from the induction period of the TUSCANY-2 Phase 2b ...
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this patient population DATROWAY also demonstrated a highly ...
Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD ...
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ...
Following a strong 12-month rally, Zenas BioPharma (ZBIO) fell sharply on Monday after the company failed to meet Wall Street ...
Zenas BioPharma shares fell sharply after the company reported favorable Phase 3 study results for obexelimab in immunoglobulin G4-related disease. The stock fell 56% to $15.22. Despite Monday's ...
As for safety, the most common adverse reactions reported with treatment were mild to moderate nausea, edema, pain in extremities and back, and fatigue. No cases of relacorilant-induced hypokalemia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback